EP Patent

EP3509581A1 — Formulations of (r

Assigned to Axsome Malta Ltd · Expires 2019-07-17 · 7y expired

What this patent protects

The present invention relates to immediate release formulations of (R) -2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

USPTO Abstract

The present invention relates to immediate release formulations of (R) -2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

Patent Metadata

Patent number: EP3509581A1
Jurisdiction: EP
Classification: —
Expires: 2019-07-17
Drug substance claim: No
Drug product claim: No
Assignee: Axsome Malta Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.